Cargando…
Systemic therapy options following first-line chemoimmunotherapy in small-cell lung cancer
Nearly all patients with extensive-stage small-cell lung cancer (ES-SCLC) relapse following first-line etoposide plus platinum (EP) with or without immune checkpoint inhibition. Topotecan and amrubicin are chemotherapies approved for these patients. The toxicities of these chemotherapies are signifi...
Autor principal: | Pacheco, Jose M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7656348/ https://www.ncbi.nlm.nih.gov/pubmed/33209465 http://dx.doi.org/10.21037/jtd.2020.03.67 |
Ejemplares similares
-
Low Risk of Hyperprogression with First-Line Chemoimmunotherapy for Advanced Non-Small Cell Lung Cancer: Pooled Analysis of 7 Clinical Trials
por: Li, Lee X, et al.
Publicado: (2023) -
Small cell lung cancer: updates and future directions
por: Pacheco, Jose M.
Publicado: (2020) -
Immunotherapy for extensive stage small cell lung cancer
por: Pacheco, Jose M.
Publicado: (2020) -
Systemic therapy for limited stage small cell lung carcinoma
por: Noronha, Vanita, et al.
Publicado: (2020) -
What is the role of consolidative thoracic radiotherapy in the era of chemo-immunotherapy for extensive stage small cell lung cancer?
por: Higgins, Kristin A., et al.
Publicado: (2020)